Asia-Pacific accounts for over 30% of global clinical trial activity and is growing faster than any other region. ClinTrust.ai is headquartered in Singapore and designed from the ground up for APAC's regulatory, banking, and operational realities.
Singapore sits at the center of Asia-Pacific's clinical research ecosystem — geographically, regulatory, and financially. As the region's leading financial hub with advanced payment infrastructure, robust clinical research regulation, and deep talent depth in life sciences and fintech, Singapore is the natural home base for a clinical trial payment infrastructure business.
ClinTrust.ai optimizes payment routing for each APAC market, using the fastest available local rails with full FX transparency and regulatory compliance for each corridor.
Cross-border clinical trial payments have historically carried opaque FX conversion costs embedded by correspondent banks. ClinTrust.ai provides full rate disclosure, conversion cost transparency, and local currency disbursement to eliminate hidden payment value erosion.
ClinTrust.ai is designed to operate within the regulatory frameworks of each APAC market — from ICH alignment to local clinical trial ordinances.
Whether you're a global pharma expanding into APAC or a regional sponsor optimizing existing operations, ClinTrust.ai provides the payment infrastructure your trial program needs.